

Behnood Bikdeli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7864953/publications.pdf>

Version: 2024-02-01

151
papers

13,107
citations

136950

32
h-index

25787

108
g-index

155
all docs

155
docs citations

155
times ranked

21067
citing authors

#	ARTICLE	IF	CITATIONS
1	Pulmonary Embolism in Patients with COVID-19: Comparison between Different Care Settings. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 034-046.	2.7	6
2	Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 131-141.	3.4	55
3	Machine Learning to Predict Outcomes in Patients with Acute Pulmonary Embolism Who Prematurely Discontinued Anticoagulant Therapy. <i>Thrombosis and Haemostasis</i> , 2022, 122, 570-577.	3.4	10
4	RIETE Registry: Past, Present and Future. <i>Archivos De Bronconeumologia</i> , 2022, 58, 205-207.	0.8	4
5	Randomised controlled trial of a prognostic assessment and management pathway to reduce the length of hospital stay in normotensive patients with acute pulmonary embolism. <i>European Respiratory Journal</i> , 2022, 59, 2100412.	6.7	11
6	Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism. <i>Chest</i> , 2022, 161, 524-534.	0.8	14
7	Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 677-686.	3.0	45
8	Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in Patients with Provoked Venous Thromboembolism and Enduring Risk Factors: Rationale and Design of the HI-PRO Trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1061-1070.	3.4	4
9	Ventilation/perfusion (V/Q) scanning in contemporary patients with pulmonary embolism: utilization rates and predictors of use in a multinational study. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 829-840.	2.1	6
10	Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. <i>European Heart Journal</i> , 2022, 43, 959-967.	2.2	79
11	A Pulmonary Embolism Diagnostic Strategy in Patients Hospitalized for COPD Exacerbation—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 184.	7.4	0
12	Prognostic impact of acute kidney injury in patients with acute pulmonary embolism data from the RIETE registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 58-66.	2.1	3
13	Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry. <i>Viruses</i> , 2022, 14, 178.	3.3	18
14	In patients hospitalized with COVID-19, therapeutic- vs. prophylactic-dose heparin did not reduce a composite outcome at 28 d. <i>Annals of Internal Medicine</i> , 2022, , .	3.9	1
15	In high-risk inpatients with COVID-19, therapeutic- vs. standard-dose heparin reduced thromboembolism or death at 30 d. <i>Annals of Internal Medicine</i> , 2022, , .	3.9	0
16	Clinical characteristics, time course, and outcomes of major bleeding according to bleeding site in patients with venous thromboembolism. <i>Thrombosis Research</i> , 2022, 211, 10-18.	1.7	4
17	Response. <i>Chest</i> , 2022, 161, e131-e132.	0.8	2
18	Comparison of Full-Dose vs. Moderate-Dose Systemic Thrombolysis for the Treatment of Patients With Acute Pulmonary Embolism. <i>Chest</i> , 2022, 162, 448-451.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Major bleeding in patients with pulmonary embolism presenting with syncope. <i>European Journal of Clinical Investigation</i> , 2022, , e13774.	3.4	0
20	Adjusted D-dimer cutoff levels to rule out pulmonary embolism in patients hospitalized for COPD exacerbation: results from the SLICE trial. <i>Thrombosis Journal</i> , 2022, 20, 10.	2.1	2
21	Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment. <i>Contemporary Clinical Trials</i> , 2022, 115, 106714.	1.8	3
22	Tissue plasminogen activator for the treatment of adults with critical COVID-19: A pilot randomized clinical trial. <i>Thrombosis Research</i> , 2022, 216, 125-128.	1.7	10
23	Effect of Prognostic Guided Management of Patients With Acute Pulmonary Embolism According to the European Society of Cardiology Risk Stratification Model. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 872115.	2.4	2
24	Statin use and 30-day mortality in patients with acute symptomatic pulmonary embolism. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1839-1851.	3.8	4
25	Sex Differences in Presentation, Risk Factors, Drug and Interventional Therapies, and Outcomes of Elderly Patients with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study. <i>Thrombosis Research</i> , 2022, 214, 122-131.	1.7	3
26	Untreated obstructive sleep apnea and cardiovascular outcomes in patients with acute symptomatic pulmonary embolism. <i>Thrombosis Research</i> , 2022, 214, 87-92.	1.7	4
27	To escalate thromboprophylactic heparin intensity in COVID-19 or not? That is still the question. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12738.	2.3	2
28	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. <i>JAMA Cardiology</i> , 2022, 7, 747.	6.1	15
29	Clinical Presentation and Short- and Long-term Outcomes in Patients With Isolated Distal Deep Vein Thrombosis vs Proximal Deep Vein Thrombosis in the RIETE Registry. <i>JAMA Cardiology</i> , 2022, 7, 857.	6.1	15
30	Management of isolated distal deep vein thrombosis with direct oral anticoagulants in the RIETE registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 532-541.	2.1	4
31	Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019. <i>Chest</i> , 2021, 159, 1182-1196.	0.8	361
32	Prognostic significance of computed tomography-assessed right ventricular enlargement in low-risk patients with pulmonary embolism: Systematic review and meta-analysis. <i>Thrombosis Research</i> , 2021, 197, 48-55.	1.7	6
33	Advanced Therapies for Acute Pulmonary Embolism: A Focus on Catheter-Based Therapies and Future Directions. <i>Structural Heart</i> , 2021, 5, 103-119.	0.6	4
34	Safety of Apixaban for Cancer-Associated Thrombosis. <i>Thrombosis and Haemostasis</i> , 2021, 121, 547-551.	3.4	2
35	Clinical Implications of the ISCHEMIA Trial: Invasive vs Conservative Approach in Stable Coronary Disease. <i>Current Cardiology Reports</i> , 2021, 23, 43.	2.9	2
36	Post-acute COVID-19 syndrome. <i>Nature Medicine</i> , 2021, 27, 601-615.	30.7	3,051

#	ARTICLE	IF	CITATIONS
37	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1903-1921.	2.8	150
38	Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1620.	7.4	515
39	Response. <i>Chest</i> , 2021, 159, 2513.	0.8	0
40	Bleeding risk in hospitalized patients with COVID-19 receiving intermediate- or therapeutic doses of thromboprophylaxis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1981-1989.	3.8	42
41	Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 78, 408-411.	2.8	44
42	Refinement of a modified simplified Pulmonary Embolism Severity Index for elderly patients with acute pulmonary embolism. <i>International Journal of Cardiology</i> , 2021, 335, 111-117.	1.7	1
43	Images in Vascular Medicine: Pulmonary embolism and acute aortic syndromes â€œ Double trouble when vascular medicine emergencies meet. <i>Vascular Medicine</i> , 2021, , 1358863X2110296.	1.5	0
44	Thromboprophylaxis strategies to improve the prognosis of COVID-19. <i>Vascular Pharmacology</i> , 2021, 139, 106883.	2.1	7
45	Difference between Japanese and White patients with acute pulmonary embolism. <i>Thrombosis Research</i> , 2021, 204, 52-56.	1.7	5
46	Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3080-3089.	3.8	13
47	Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism. <i>Journal of the American Heart Association</i> , 2021, 10, e021467.	3.7	4
48	Presenting Characteristics, Treatment Patterns, and Outcomes among Patients with Venous Thromboembolism during Hospitalization for COVID-19. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 351-361.	2.7	34
49	Prognostic Impact of Obstructive Sleep Apnea in Patients Presenting with Acute Symptomatic Pulmonary Embolism. <i>Thrombosis and Haemostasis</i> , 2021, 121, 808-815.	3.4	12
50	Clinical characteristics and 3-month outcomes in cancer patients with incidental <i>versus</i> clinically suspected and confirmed pulmonary embolism. <i>European Respiratory Journal</i> , 2021, 58, 2002723.	6.7	9
51	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1635-1654.	2.8	42
52	Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1277.	7.4	28
53	Vaccine-induced immune thrombotic thrombocytopenia after the BNT162b2 mRNA Covid-19 vaccine: A case study. <i>Thrombosis Research</i> , 2021, 208, 1-3.	1.7	7
54	Pulmonary embolism in Europe remains a cause of concern despite declining deaths. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 222-224.	10.7	4

#	ARTICLE	IF	CITATIONS
55	Atrial fibrillation in the course of pulmonary embolism: just a little smoke, or fuel to the fire?. <i>Journal of Internal Medicine</i> , 2020, 287, 114-116.	6.0	5
56	Zinc Deficiency and Heart Failure: A Systematic Review of the Current Literature. <i>Journal of Cardiac Failure</i> , 2020, 26, 180-189.	1.7	28
57	Systolic blood pressure and mortality in acute symptomatic pulmonary embolism. <i>International Journal of Cardiology</i> , 2020, 302, 157-163.	1.7	13
58	Subsegmental pulmonary embolism: May not be a killer but indicates significant risk. <i>Thrombosis Research</i> , 2020, 185, 180-182.	1.7	1
59	Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. <i>Thrombosis and Haemostasis</i> , 2020, 120, 348-362.	3.4	13
60	Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism: Findings from the Registro Informatizado de Enfermedad Tromboembólica Registry. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2020, 8, 353-359.e1.	1.6	10
61	Anticoagulation in COVID-19: Randomized trials should set the balance between excitement and evidence. <i>Thrombosis Research</i> , 2020, 196, 638-640.	1.7	11
62	Derivation and validation of a clinical prediction rule for thrombolysis-associated major bleeding in patients with acute pulmonary embolism: the BACS score. <i>European Respiratory Journal</i> , 2020, 56, 2002336.	6.7	30
63	Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1640.	7.4	112
64	Real-Time Dissemination of Aggregate Data on Presentation and Outcomes of Patients With Venous Thromboembolism: The RIETE Infographics Project. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962093120.	1.7	1
65	Non-inferiority trials using a surrogate marker as the primary endpoint: An increasing phenotype in cardiovascular trials. <i>Clinical Trials</i> , 2020, 17, 723-728.	1.6	0
66	Pharmacotherapy for Prevention and Management of Thrombosis in COVID-19. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 789-795.	2.7	12
67	Association between reperfusion therapy and outcomes in patients with acute pulmonary embolism and right heart thrombi. <i>European Respiratory Journal</i> , 2020, 56, 2000538.	6.7	6
68	Outcomes after Vena Cava Filter Use in Patients with Cancer-Associated Venous Thromboembolism and Contraindications to Anticoagulation. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1035-1044.	3.4	10
69	Patient-Level, Institutional, and Temporal Variations in Use of Imaging Modalities to Confirm Pulmonary Embolism. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e010651.	2.6	8
70	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	3.4	206
71	Outcome of patients with acute symptomatic pulmonary embolism and psychiatric disorders. <i>Thrombosis Research</i> , 2020, 193, 90-97.	1.7	3
72	Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2352-2371.	2.8	1,557

#	ARTICLE	IF	CITATIONS
73	Extrapulmonary manifestations of COVID-19. <i>Nature Medicine</i> , 2020, 26, 1017-1032.	30.7	2,300
74	Recent trends in use of inferior vena caval filters in US older adults with acute pulmonary embolism. <i>Thrombosis Research</i> , 2020, 186, 78-79.	1.7	2
75	Morbid Obesity and Mortality in Patients With VTE. <i>Chest</i> , 2020, 157, 1617-1625.	0.8	10
76	Inferior vena cava agenesis in patients with lower limb deep vein thrombosis in the RIETE registry. When and why to suspect. <i>International Journal of Cardiology</i> , 2020, 305, 115-119.	1.7	16
77	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	2.8	2,392
78	Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. <i>Thrombosis Research</i> , 2020, 196, 382-394.	1.7	62
79	Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 908-918.	2.7	13
80	Implications of Abnormal Troponin Levels With Normal Right Ventricular Function in Normotensive Patients With Acute Pulmonary Embolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962096776.	1.7	2
81	Zinc Deficiency as a Reversible Cause of Heart Failure. <i>Texas Heart Institute Journal</i> , 2020, 47, 152-154.	0.3	16
82	Hospital volume and outcomes for acute pulmonary embolism: multinational population based cohort study. <i>BMJ: British Medical Journal</i> , 2019, 366, l4416.	2.3	41
83	Pulmonary Embolism Hospitalization, Readmission, and Mortality Rates in US Older Adults, 1999-2015. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 574.	7.4	69
84	Statin and all-cause mortality in patients receiving anticoagulant therapy for venous thromboembolism. Data from the RIETE registry. <i>European Journal of Internal Medicine</i> , 2019, 68, 30-35.	2.2	12
85	Use of Prophylaxis for Prevention of Venous Thromboembolism in Patients with Isolated Foot or Ankle Surgery: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1686-1694.	3.4	8
86	Venous Thromboembolism in Patients with Liver Cirrhosis: Findings from the RIETE (Registro) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 227 2019, 45, 793-801.	2.7	12
87	Hemopericardium and Cardiac Tamponade as a Complication of Vena Caval Filters: Systematic Review of the Published Literature and the MAUDE Database. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961984911.	1.7	2
88	Noninferiority Designed Cardiovascular Trials in Highest-Impact Journals. <i>Circulation</i> , 2019, 140, 379-389.	1.6	24
89	Revisiting Results on Use of Inferior Vena Cava Filters in Older Adultsâ€™Reply. <i>JAMA Internal Medicine</i> , 2019, 179, 727.	5.1	0
90	Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism. <i>Internal and Emergency Medicine</i> , 2019, 14, 1101-1112.	2.0	9

#	ARTICLE	IF	CITATIONS
91	Venous thromboembolism in young adults: Findings from the RIETE registry. <i>European Journal of Internal Medicine</i> , 2019, 63, 27-33.	2.2	10
92	Intermediate-High Risk Pulmonary Embolism. <i>TH Open</i> , 2019, 03, e356-e363.	1.4	23
93	Accuracy and Interobserver Reliability of the Simplified Pulmonary Embolism Severity Index Versus the Hestia Criteria for Patients With Pulmonary Embolism. <i>Academic Emergency Medicine</i> , 2019, 26, 394-401.	1.8	16
94	Meta-Analysis of Prevalence and Short-Term Prognosis of Hemodynamically Unstable Patients With Symptomatic Acute Pulmonary Embolism. <i>American Journal of Cardiology</i> , 2019, 123, 684-689.	1.6	36
95	Association of Inferior Vena Cava Filter Use With Mortality Rates in Older Adults With Acute Pulmonary Embolism. <i>JAMA Internal Medicine</i> , 2019, 179, 263.	5.1	9
96	Assessment of coexisting deep vein thrombosis for risk stratification of acute pulmonary embolism. <i>Thrombosis Research</i> , 2018, 164, 40-44.	1.7	12
97	Impact of Thrombus Sidedness on Presentation and Outcomes of Patients with Proximal Lower Extremity Deep Vein Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 341-347.	2.7	12
98	Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE). <i>Thrombosis and Haemostasis</i> , 2018, 118, 214-224.	3.4	160
99	Performance of Early Prognostic Assessment Independently Predicts the Outcomes in Patients with Acute Pulmonary Embolism. <i>Thrombosis and Haemostasis</i> , 2018, 47, 798-800.	3.4	5
100	Systematic review of efficacy and safety of retrievable inferior vena caval filters. <i>Thrombosis Research</i> , 2018, 165, 79-82.	1.7	10
101	Thirty-day outcomes in patients with acute pulmonary embolism who discontinued anticoagulant therapy before 90 days. <i>American Heart Journal</i> , 2018, 206, 1-10.	2.7	10
102	Early Use of Echocardiography in Patients With Acute Pulmonary Embolism: Findings From the RIETE Registry. <i>Journal of the American Heart Association</i> , 2018, 7, e009042.	3.7	31
103	Arterial Ischemic Events Are a Major Complication in Cancer Patients with Venous Thromboembolism. <i>American Journal of Medicine</i> , 2018, 131, 1095-1103.	1.5	41
104	Scores to Identify Occult Cancer in Venous Thromboembolism: Do They Work?. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1343-1344.	3.4	1
105	National and Regional Trends in Deep Vein Thrombosis Hospitalization Rates, Discharge Disposition, and Outcomes for Medicare Beneficiaries. <i>American Journal of Medicine</i> , 2018, 131, 1200-1208.	1.5	12
106	Epidemiology, patterns of care and mortality for patients with hemodynamically unstable acute symptomatic pulmonary embolism. <i>International Journal of Cardiology</i> , 2018, 269, 327-333.	1.7	41
107	Management appropriateness and outcomes of patients with acute pulmonary embolism. <i>European Respiratory Journal</i> , 2018, 51, 1800445.	6.7	33
108	Aggressive Treatment of Intermediate-Risk Patients with Acute Symptomatic Pulmonary Embolism. <i>Clinics in Chest Medicine</i> , 2018, 39, 569-581.	2.1	8

#	ARTICLE	IF	CITATIONS
109	Age of Data at the Time of Publication of Contemporary Clinical Trials. JAMA Network Open, 2018, 1, e181065.	5.9	23
110	Bivalirudin bewilderment. Kardiologia Polska, 2018, 76, 711-712.	0.6	2
111	Pulmonary Embolism and Atrial Fibrillation: Two Sides of the Same Coin? A Systematic Review. Seminars in Thrombosis and Hemostasis, 2017, 43, 849-863.	2.7	45
112	Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990â€“2011. Journal of the American Heart Association, 2017, 6, .	3.7	37
113	Inferior Vena Cava Filters to Prevent Pulmonary Embolism. Journal of the American College of Cardiology, 2017, 70, 1587-1597.	2.8	134
114	Data Desert for Inferior Vena Caval Filters. JAMA Cardiology, 2017, 2, 3.	6.1	14
115	Systemic thrombolysis in a patient with massive pulmonary embolism and recent glioblastoma multiforme resection. BMJ Case Reports, 2017, 2017, bcr-2017-221578.	0.5	2
116	Updates on Advanced Therapies for Acute Pulmonary Embolism. International Journal of Cardiovascular Practice, 2016, 1, 1-4.	0.2	8
117	Hospitalizations, Therapies, and Outcomes of Pulmonary Embolism in Medicare Beneficiaries. Journal of the American College of Cardiology, 2016, 67, 2559-2560.	2.8	8
118	Response to Letter Regarding Article, â€œPoorly Cited Articles in Peer-Reviewed Cardiovascular Journals from 1997 to 2007: Analysis of 5-Year Citation Ratesâ€• Circulation, 2016, 133, e23-4.	1.6	0
119	Pulmonary Embolism As a Consequence of Ultrasonographic Examination of Extremities for Suspected Venous Thrombosis: A Systematic Review. Seminars in Thrombosis and Hemostasis, 2016, 42, 636-641.	2.7	8
120	Vena Caval Filter Utilization and Outcomes in Pulmonary Embolism. Journal of the American College of Cardiology, 2016, 67, 1027-1035.	2.8	61
121	Smoking and wound complications after coronary artery bypass grafting. Journal of Surgical Research, 2016, 200, 743-748.	1.6	19
122	Changes in Hospitalizations, Treatment Patterns, and Outcomes During Major Cardiovascular Meetings. JAMA Internal Medicine, 2015, 175, 1419.	5.1	0
123	Risk of Stent Thrombosis and Major Bleeding with Bivalirudin Compared with Active Control: A Systematic Review and Meta-analysis of Randomized Trials. Thrombosis Research, 2015, 136, 1087-1098.	1.7	17
124	Intravenous Fluids in Acute Decompensated Heart Failure. JACC: Heart Failure, 2015, 3, 127-133.	4.1	31
125	Poorly Cited Articles in Peer-Reviewed Cardiovascular Journals from 1997 to 2007. Circulation, 2015, 131, 1755-1762.	1.6	30
126	Infective endocarditis and antibiotic prophylaxis. Lancet, The, 2015, 386, 528-529.	13.7	1

#	ARTICLE	IF	CITATIONS
127	National Trends in Pulmonary Embolism Hospitalization Rates and Outcomes for Adults Aged ≥65 Years in the United States (1999 to 2010). American Journal of Cardiology, 2015, 116, 1436-1442.	1.6	57
128	Hospital Variation in Noninvasive Positive Pressure Ventilation for Acute Decompensated Heart Failure. Circulation: Heart Failure, 2014, 7, 427-433.	3.9	10
129	Place of Residence and Outcomes of Patients With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 749-756.	2.2	53
130	Therapies for Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2014, 311, 2543.	7.4	2
131	Use of Intravenous Diuretics on Day of Discharge in Adults Hospitalized for Heart Failure. Journal of Cardiac Failure, 2014, 20, 706-707.	1.7	3
132	Omega-3 supplements and cardiovascular diseases. Tanaffos, 2014, 13, 6-14.	0.5	7
133	Dominance of Furosemide for Loop Diuretic Therapy in Heart Failure. Journal of the American College of Cardiology, 2013, 61, 1549-1550.	2.8	50
134	Trends in Hospitalization Rates and Outcomes of Endocarditis Among Medicare Beneficiaries. Journal of the American College of Cardiology, 2013, 62, 2217-2226.	2.8	89
135	Comparison of three risk assessment methods for venous thromboembolism prophylaxis. Blood Coagulation and Fibrinolysis, 2013, 24, 157-163.	1.0	3
136	Most Important Outcomes Research Papers on Variation in Cardiovascular Disease. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, e9-16.	2.2	7
137	Most Important Outcomes Research Papers on Hypertension. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, e26-35.	2.2	4
138	Most Important Outcomes Research Papers on Cardiovascular Disease in Women. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, e1-7.	2.2	12
139	Assessment of Prophylaxis for Venous Thromboembolism in Hospitalized Patients. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 462-468.	1.7	8
140	Most Important Outcomes Research Papers in Cardiovascular Disease in the Elderly. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, e17-26.	2.2	6
141	Reducing the Cardiovascular Disease Burden. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 580-586.	2.2	8
142	Prophylaxis for Venous Thromboembolism: A Great Global Divide between Expert Guidelines and Clinical Practice?. Seminars in Thrombosis and Hemostasis, 2012, 38, 144-155.	2.7	26
143	Most Important Articles on Cardiovascular Disease Among Racial and Ethnic Minorities. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, e33-41.	2.2	32
144	When the game demons take real lives: A call for global awareness raising for venous Thromboembolism. Thrombosis Research, 2012, 129, 207.	1.7	6

#	ARTICLE	IF	CITATIONS
145	Most Important Outcomes Research Papers on Anticoagulation for Cardiovascular Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, e65-74.	2.2	14
146	Chest physicians'™ knowledge of appropriate thromboprophylaxis. <i>Blood Coagulation and Fibrinolysis</i> , 2011, 22, 667-672.	1.0	9
147	C-Reactive Protein, Statins and the Risk of Vascular Events: A Better Understanding. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 545-549.	2.6	6
148	Dexter versus Sinister Deep Vein Thrombosis: Which Is the More Sinister? Findings from the NRITLD DVT Registry. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 298-304.	2.7	8
149	Coexisting venous thromboembolism in patients with tuberculosis. <i>Thrombosis Research</i> , 2010, 125, 478-480.	1.7	17
150	Sticker reminders improve thromboprophylaxis appropriateness in hospitalized patients. <i>Thrombosis Research</i> , 2010, 126, 211-216.	1.7	21
151	Pathophysiology of Aortocoronary Saphenous Vein Bypass Graft Disease. <i>Asian Cardiovascular and Thoracic Annals</i> , 2008, 16, 331-336.	0.5	44